Inherent Biosciences Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5M
- Investors
-
18
Inherent Biosciences General Information
Description
Developer of an epigenetic medicine platform designed to tackle health issues by overhauling the trial-and-error methodology. The company's platform detects dysregulation across multiple genes and related pathways to pioneer a new category of diagnostics and therapeutics that leverage epigenetics along with lifestyle effects on the probability of a positive reproduction, enabling doctors and physicians to guide patients with complex diseases.
Contact Information
Website
www.inherentbio.comCorporate Office
- 26 South Rio Grande Street
- Suite 2072
- Salt Lake City, UT 84101
- United States
Corporate Office
- 26 South Rio Grande Street
- Suite 2072
- Salt Lake City, UT 84101
- United States
Inherent Biosciences Timeline
Inherent Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 06-Apr-2026 | $5M | Completed | Generating Revenue | ||
| 10. Early Stage VC (Series A) | 07-Sep-2025 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | 05-Mar-2023 | Completed | Generating Revenue | |||
| 8. Grant | 16-Aug-2023 | Completed | Generating Revenue | |||
| 7. Early Stage VC (Series A) | 15-Sep-2022 | Completed | Generating Revenue | |||
| 6. Grant | 01-Apr-2022 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 15-Oct-2021 | Completed | Generating Revenue | |||
| 4. Angel (individual) | 01-Dec-2020 | Completed | Generating Revenue | |||
| 3. Seed Round | 26-Oct-2020 | $1.75M | $1.75M | Completed | Generating Revenue | |
| 2. Grant | 09-Sep-2020 | $256K | Completed | Generating Revenue |
Inherent Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A-1 | 3,000,000 | $0.001000 | $0.09 | $1.58 | $1.58 | 1x | $1.58 | 26.25% |
| Seed | 1,207,149 | $0.001000 | $0.88 | $0.88 | 1x | $0.88 | 10.56% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Inherent Biosciences Comparisons
Industry
Financing
Details
Inherent Biosciences Competitors (75)
One of Inherent Biosciences’s 75 competitors is Genetix Biotherapeutics, a Private Equity-Backed company based in Somerville, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Sphere Fluidics | Formerly VC-backed | Cambridge, United Kingdom | ||||
| Frontier Medicines | Venture Capital-Backed | San Francisco, CA | ||||
| Personal Genome Diagnostics | Formerly VC-backed | Baltimore, MD | ||||
| Arvinas | Formerly VC-backed | New Haven, CT |
Inherent Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Inherent Biosciences Patents
Inherent Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3233857-A1 | Methods and systems for predicting sperm quality | Pending | 06-Oct-2021 | ||
| EP-4413162-A1 | Methods and systems for predicting sperm quality | Active | 06-Oct-2021 | ||
| EP-4782553-A2 | Methods and systems for predicting sperm quality | Pending | 06-Oct-2021 | ||
| EP-4782553-A3 | Methods and systems for predicting sperm quality | Pending | 06-Oct-2021 | ||
| US-20250179574-A1 | Methods and systems for predicting sperm quality | Pending | 06-Oct-2021 | C12Q1/6883 |
Inherent Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Inherent Biosciences Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cadron Capital Partners | Venture Capital | Minority | ||
| HealthTech Investors | Angel Group | Minority | ||
| Nucleus Fund | Venture Capital | Minority | ||
| Regent Partners (Seoul) | Venture Capital | Minority | ||
| Samothrace Partners | Angel Group | Minority |
Inherent Biosciences FAQs
-
When was Inherent Biosciences founded?
Inherent Biosciences was founded in 2019.
-
Where is Inherent Biosciences headquartered?
Inherent Biosciences is headquartered in Salt Lake City, UT.
-
What is the size of Inherent Biosciences?
Inherent Biosciences has 15 total employees.
-
What industry is Inherent Biosciences in?
Inherent Biosciences’s primary industry is Biotechnology.
-
Is Inherent Biosciences a private or public company?
Inherent Biosciences is a Private company.
-
What is Inherent Biosciences’s current revenue?
The current revenue for Inherent Biosciences is .
-
How much funding has Inherent Biosciences raised over time?
Inherent Biosciences has raised $14.8M.
-
Who are Inherent Biosciences’s investors?
Cadron Capital Partners, HealthTech Investors, Nucleus Fund, Regent Partners (Seoul), and Samothrace Partners are 5 of 18 investors who have invested in Inherent Biosciences.
-
Who are Inherent Biosciences’s competitors?
Genetix Biotherapeutics, Sphere Fluidics, Frontier Medicines, Personal Genome Diagnostics, and Arvinas are some of the 75 competitors of Inherent Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
